NTRK1 and lung carcinoma: Several EGFR-targeting therapeutic agents are currently used for patients with EGFR-positive lung cancer, including receptor tyrosine kinase inhibitors such as afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib.